Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NutraMax private label clotrimazole

This article was originally published in The Tan Sheet

Executive Summary

Gloucester, Mass.-based private label firm said it "anticipates first shipments to begin in late fall, 1993." NutraMax said it has signed "an exclusive manufacturing and supply agreement" with an undisclosed supplier covering private label products containing clotrimazole in both cream and insert forms. Currently, the only companies with approval to manufacture and market OTC clotrimazole products for yeast infections are Schering-Plough (Gyne-Lotrimin) and Miles (Mycelex). Schering- Plough, which has sought to delay generic clotrimazole approvals by petitioning FDA to set tougher standards for topical products, said it is not supplying NutraMax. The private label firm said its clotrimazole products will retail at a 30-45% discount to J&J's Monistat 7 and Gyne-Lotrimin.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081668

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel